- ISIN
- US1421521071
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 18, 2025
Highlights
- Market Cap
- $4.97B
- Enterprise Value
- $4.15B
- EPS (TTM)
- $0.05
- PE Ratio
- 327.30
- PEG Ratio
- 1.25
- Total Revenue (TTM)
- $907.29M
- Gross Profit (TTM)
- $482.11M
- EBITDA (TTM)
- $92.24M
- Year Range
- $14.19 - $42.50
- Target Price
- $28.75
- ROA (TTM)
- 2.92%
- ROE (TTM)
- 5.73%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CAI Performance Chart
Caris Life Sciences, Inc (CAI) is down 34.8% since the beginning of the year. At $18 per share, CAI is trading 58.6% below its 52-week high of $43.
Loading charts...
Returns By Period
Caris Life Sciences, Inc (CAI) has returned -34.77% so far this year and -32.15% over the past 12 months.
Caris Life Sciences, Inc
- 1D
- 1.68%
- 1M
- 13.18%
- YTD
- -34.77%
- 6M
- -37.14%
- 1Y
- -32.15%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
CAI Monthly Returns History
Based on dividend-adjusted daily data since Jun 18, 2025, CAI's average daily return is -0.09%, while the average monthly return is -2.26%.
Historically, 38% of months were positive and 62% were negative. The best month was Aug 2025 with a return of +36.7%, while the worst month was Sep 2025 at -21.2%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.
On a daily basis, CAI closed higher 47% of trading days. The best single day was Jun 4, 2026 with a return of +11.6%, while the worst single day was May 8, 2026 at -18.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.16% | -13.04% | -11.22% | 6.26% | -12.00% | 5.26% | -34.77% | ||||||
| 2025 | -1.04% | 5.09% | 36.72% | -21.20% | -0.56% | -15.13% | 5.68% | -0.07% |
Benchmark Metrics
Caris Life Sciences, Inc has an annualized alpha of -42.07%, beta of 1.50, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 18, 2025.
- This stock participated in 154.59% of S&P 500 Index downside but only -63.02% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -42.07%
- Beta
- 1.50
- R²
- 0.09
- Upside Capture
- -63.02%
- Downside Capture
- 154.59%
Return for Risk
Risk / Return Rank
CAI ranks 23 for risk / return — below 23% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Caris Life Sciences, Inc (CAI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CAI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.30 | ||
| Sortino ratioReturn per unit of downside risk | -2.84 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.32 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.51 | 2.46 | -2.97 |
| Martin ratioReturn relative to average drawdown | -0.85 | 10.92 | -11.77 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Caris Life Sciences, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Caris Life Sciences, Inc was 62.98%, occurring on May 15, 2026. The portfolio has not yet recovered.
The current Caris Life Sciences, Inc drawdown is 55.22%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -62.98%May 2026 | 8mo 23d | — | 10mo 3dAug 2025 - now |
2025 correction2025 | -13.82%Jul 2025 | 11d | 15d | 26dJul 2025 - Aug 2025 |
2025 selloff2025 | -7.36%Jun 2025 | 3d | 22d | 25dJun 2025 - Jul 2025 |
2025 pullback2025 | -5.19%Aug 2025 | 5d | 1d | 6dAug 2025 - Aug 2025 |
Drawdown Indicators
| CAI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.98% | -56.78% | -6.20% |
Max Drawdown (1Y)Largest decline over 1 year | -62.98% | -9.10% | -53.88% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -55.22% | -3.21% | -52.01% |
Average DrawdownAverage peak-to-trough decline | -32.18% | -10.71% | -21.47% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.66% | 2.04% | +35.62% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Caris Life Sciences, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Caris Life Sciences, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CAI, comparing it with other companies in the Biotechnology industry. Currently, CAI has a P/E ratio of 327.3. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CAI compared to other companies in the Biotechnology industry. CAI currently has a PEG ratio of 1.3. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CAI relative to other companies in the Biotechnology industry. Currently, CAI has a P/S ratio of 12.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CAI in comparison with other companies in the Biotechnology industry. Currently, CAI has a P/B value of 8.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CAI
Add Caris Life Sciences, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CAI